Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 0.80 |
| ▸ | POLB | P06746 | 3/20 | 0.74 |
| ▸ | APEX1 | P27695 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532179 | 0.89 | LMNA (1.00) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL14485232 | 0.89 | MAPT (0.82) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL13532182 | 0.88 | SMN1; SMN2 (0.78) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL14291713 | 0.86 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL16085394 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL19631199 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL28091841 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL13532153 | 0.83 | LMNA (0.70) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL22516268 | 0.82 | ALDH1A1 (0.78) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL18948462 | 0.82 | LMNA (0.69) | SMN1; SMN2LMNAMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070703-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | UNIV DREXEL (US) | 2021-03-11 | — | — | US | claimed |
| EP-2726459-B1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | BARUCH S BLUMBERG INST (US) | 2019-09-11 | — | — | EP | claimed |
| WO-2019046287-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-07 | — | — | WO | claimed |
| US-20170320818-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | UNIV DREXEL (US) | 2017-11-09 | — | — | US | claimed |
| EP-3085368-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | Baruch S. Blumberg Institute (US) | 2016-10-26 | — | — | EP | claimed |
| US-9399619-B2 | Sulfamoylbenzamide derivatives as antiviral agents against HBV infection | BARUCH S. BLUMBERG INSTITUTE (US) | 2016-07-26 | — | — | US | claimed |
| US-20160101074-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE | 2016-04-14 | — | — | US | claimed |
| US-20140206666-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | Philadelphia Helath & Education Corporation d/b/a Drexel University College of Medicine (US) | 2014-07-24 | — | — | US | claimed |
| EP-2726459-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | Institute for Hepatitis and Virus Research (US) | 2014-05-07 | — | — | EP | claimed |
| WO-2013006394-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) | 2013-01-10 | — | — | WO | claimed |
| WO-2019046287-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-07 | — | — | WO | disclosed |
| EP-3085368-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | Baruch S. Blumberg Institute (US) | 2016-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101074-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | ALKBH5, SULT1A1, SHMT1 | SMN1; SMN2 3413/4885LMNA 2634/4885MEN1 4626/4885 |
| US-20170320818-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | ALKBH5, SULT1A1, SHMT1 | SMN1; SMN2 3413/4885LMNA 2634/4885MEN1 4626/4885 |
| US-20210070703-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | ALKBH5, SULT1A1, SHMT1 | SMN1; SMN2 3413/4885LMNA 2634/4885MEN1 4626/4885 |
| US-20140206666-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, PHB1, BST2 | SMN1; SMN2 4170/4885LMNA 2389/4885MEN1 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.